The Novo, Pfizer and Nan Fung-backed oncology therapy developer priced an upsized offering above its range and is now valued above $1bn.

Bolt Biotherapeutics, a US-based cancer drug developer that counts pharmaceutical firms Pfizer and Novo and real estate developer Nan Fung as investors, went public on Friday raising $230m. The company issued 11.5 million shares priced at $20 each in the initial public offering, increased from 8.8 million, while the share price was above the IPO’s…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.